(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/208054 A1

(51) International Patent Classification:
C12N 15/86 (2006.01) *A61P 35/00* (2006.01)
A61K 35/766 (2015.01)

(21) International Application Number:
PCT/US2025/022071

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/570,881 28 March 2024 (28.03.2024) US
63/660,073 14 June 2024 (14.06.2024) US

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **VYRIAD, INC.** [US/US]; 2900 37th Street, NW, Building 110, Rochester, Minnesota 55901 (US).

(72) Inventors: **DADI-MEHMETAJ, Saida**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **MARGUERITE BAUMANN, Mattie**; c/o Vyriad, Inc., 2900 37th Street, NW, Building 110, Rochester, Minnesota 55901 (US). **PACKIRISWAMY, Nandakumar**; c/o Vyriad, Inc., 2900 37th Street, NW, Building 110, Rochester, Minnesota 55901 (US). **J. RUSSELL, Stephen**; c/o Vyriad, Inc., 2900 37th Street, NW, Building 110, Rochester, Minnesota 55901 (US).

(74) Agent: **CRIMINS, Johanna L.** et al.; Troutman Pepper Locke LLP, 875 Third Avenue, New York, New York 10022 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*
— *with information concerning incorporation by reference of missing element or part (Rule 20.6)*

(54) Title: RECOMBINANT RHABDOVIRUS ENCODING INTERLEUKIN-12 (IL-12)

(57) Abstract: The application relates to a recombinant virus comprising a rhabdovirus genome, e.g., a vesicular stomatitis virus (VSV) genome, and a nucleotide sequence encoding a recombinant protein comprising an interleukin-12 (IL-12) polypeptide, or a functional fragment or derivative thereof. In various aspects, the IL-12 polypeptide, or the functional fragment or derivative thereof, may be membrane bound. In various other aspects, the IL-12 polypeptide, or the functional fragment or derivative thereof, may not be membrane bound, e.g., may be a soluble IL-12 polypeptide, or a functional fragment or derivative thereof. The application further relates to recombinant polynucleotides and recombinant vectors encoding virus polypeptides and the recombinant protein, as well as to host cells and methods for preparing host cells that express the polypeptides. The application further relates to pharmaceutical compositions comprising the recombinant virus, and to methods for treating cancer, e.g., a tumor, using the recombinant virus.

WO 2025/208054 A1